Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
about
Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's diseaseGait dynamics in mouse models of Parkinson's disease and Huntington's disease.Preservation of function in Parkinson's disease: what's learning got to do with it?Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseRegulation of tyrosine phosphatase STEP61 by protein kinase A during motor skill learning in miceRhes is involved in striatal functionRegulation of bat echolocation pulse acoustics by striatal dopamine.Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice.Disruption of lateral olivocochlear neurons via a dopaminergic neurotoxin depresses sound-evoked auditory nerve activity.Dopamine-dependent motor learning: insight into levodopa's long-duration response.Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in miceNigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synucleinMotor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis.Motor deficits and altered striatal gene expression in aphakia (ak) mice.Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.Behavioral phenotyping of mouse models of Parkinson's disease.Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis.Role of calbindin-D28K in estrogen treatment for Parkinson's disease.α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation.A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.Protective Role of rAAV-NDI1, Serotype 5, in an Acute MPTP Mouse Parkinson's Model.Effects of a copper-deficient diet on the biochemistry, neural morphology and behavior of aged mice.Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.Mouse behavioral assays relevant to the symptoms of autism.Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated miceNociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.Effects of Bu Shen Yi Sui Capsule on Th17/Treg cytokines in C57BL/6 mice with experimental autoimmune encephalomyelitisAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.A guide to neurotoxic animal models of Parkinson's diseasePain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice.The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.Quantitative activation-induced manganese-enhanced MRI reveals severity of Parkinson's disease in miceSuccessful Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug.Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo.Modeling neurodegenerative diseases in vivo review.
P2860
Q24336655-176A2912-4DEF-4B89-8ED6-0BDF3BE3DA4AQ24812417-E01923E4-31FD-4895-93E0-8FDED22E00C8Q26853387-5529AF1F-19D3-455C-ADA8-12363A8C0B35Q27301283-8B2BF836-AAC4-4618-ABA2-BFB861E39912Q28394767-CAE1D517-E97F-40BC-ACE2-D0A4404E9954Q28589966-B34C461E-1644-4621-B531-144507202FB4Q28740694-F0FF2F71-BABC-43CE-A7D5-C60230308886Q30475706-43BA7BA5-BE16-4FDE-AD9F-183770441D39Q30492622-1397E19B-3171-472F-AE38-40670858E05AQ30502109-BCC91CA0-44A4-4C51-B1AE-B791DBD6F6BEQ30523813-D2F836AD-F66E-42ED-B4D8-B3FBA62277EAQ30633819-47DC8F03-6625-4287-8C86-9C404F05E951Q30848999-2A0BC496-6958-4DBC-8D8A-EF94DA52E936Q33303267-CAD53968-F45F-4BF4-9D3F-597307178661Q33401101-7BFA7F80-9DA9-4E5C-9A81-8818BCD59D19Q33820609-58565BB4-95FF-4A19-9AD4-8E021527E265Q33835301-BF300E4F-6B73-4982-9700-B56DE2AA1204Q33886545-ED9690A8-CA6B-45CE-91CB-537F551130C2Q33911605-3291D42F-6BB0-4645-90F8-22E81340BA01Q34095326-B0D260B2-237D-4B11-806B-D7634D122006Q34280317-21095FA5-3949-4660-8E98-46191FD87097Q34314213-40830A5C-E828-4270-9982-407E7B754D43Q34423923-4FBE0742-A3DA-4200-A139-AB99D91EB2B2Q34447834-011761C3-5F50-4D6E-A1CC-BBD39D0B3A8AQ34476803-E7BF3DCD-79B5-4CA7-B2DA-CE8A687588B0Q34699041-43B48A54-5B1A-4A2E-98BC-0A564DF9A13AQ34758776-777D7C7B-0139-4793-9792-99C4B4A71B7CQ34769948-2C1F2741-C645-4B4D-AD34-80A6EC240645Q35206570-08B903ED-49E0-45E1-9EB1-F6D846E111E4Q35589979-685E62F8-9C1C-41D4-8E19-90614F0C3AC4Q35603488-2E2DD25A-ED8D-47C6-9462-208D1D66D27BQ35664615-6FBAD4FC-D14A-42C1-8406-CE618EE620DBQ35782960-CBD7BC22-9B49-456B-A63A-C07607E208DEQ35894167-A8EBF73D-EA64-447F-AD0D-94A5593DF330Q35922870-209060CB-836A-4F57-BB42-EF97C3509C05Q35932932-6682A35D-06A3-4FBB-80B5-779E1A3A4976Q36106198-A7DA2757-B112-4BCA-B4A8-B944190212C0Q36243860-62CE90F0-3698-4FC6-BF8F-F6DDBE056772Q36259630-72054B56-3A48-4405-A5DA-7884500DB0B2Q36565642-ACF0B045-EDB2-4092-B781-4497517D2330
P2860
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@ast
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@en
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@nl
type
label
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@ast
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@en
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@nl
prefLabel
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@ast
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@en
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@nl
P2093
P1476
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.
@en
P2093
Schwarting RK
P304
P356
10.1016/S0166-4328(01)00309-6
P407
P577
2001-11-01T00:00:00Z